Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (36)

« Back to Publications

Independent SAGE as an example of effective public dialogue on scientific research

Greenhalgh T. et al, (2025), Nature Protocols, 20, 1103 - 1113

UK cancer vaccine advance - Recognising and realising opportunities.

Craddock C. et al, (2025), Cambridge prisms. Precision medicine, 3

Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.

Cruz P. et al, (2024), Vaccines, 13

Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study

Leston M. et al, (2024), JMIR Research Protocols, 13, e56271 - e56271

Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study (Preprint)

Leston M. et al, (2024)

A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).

Starkey T. et al, (2023), Scientific reports, 13

Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.

Suribhatla R. et al, (2023), British journal of haematology, 201, 813 - 823

The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research.

Fittall M. et al, (2023), British journal of cancer, 128, 1977 - 1980

Safe prescribing in cancer patients during the COVID-19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) team.

Appanna N. et al, (2023), International journal of cancer, 152, 1275 - 1277

Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review.

Al Hajji Y. et al, (2022), British journal of cancer, 127, 1827 - 1836

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.

Lee LYW. et al, (2022), European journal of cancer (Oxford, England : 1990), 175, 1 - 10

Machine learning for determining lateral flow device results for testing of SARS-CoV-2 infection in asymptomatic populations.

LFD AI Consortium. Electronic address: a.beggs@bham.ac.uk . and LFD AI Consortium ., (2022), Cell reports. Medicine, 3

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.

Lee LYW. et al, (2022), The Lancet. Oncology, 23, 748 - 757

Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

Várnai C. et al, (2022), JAMA Network Open, 5, e220130 - e220130

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral Flow Devices to Prevent Transmission

Lee LYW. et al, (2022), Clinical Infectious Diseases, 74, 407 - 415

Load More